The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022

Su，Shihao1; Chen，Yutong1; Zhang，Pengfei1; Ma，Ruijuan1; Zhang，Wei1; Liu，Jianing1; Li，Tao1; Niu，Hanjing1; Cao，Yi1; Hu，Bin1; Gao，Jinhua1; Sun，Hua1; Fang，Dong1; Wang，Jiajia3; Wang，Peng George4; Xie，Songqiang1; Wang，Chaojie2; Ma，Jing1

2022-12-05

10.1016/j.ejmech.2022.114680

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY   影响因子和分区

0223-5234

1768-3254

Platinum-based antitumor drugs have been used in many types of tumors due to its broad antitumor spectrum in clinic. Encouraged by the cisplatin's (CDDP) worldwide success in cancer chemotherapy, the research in platinum-based antitumor drugs has evolved from traditional platinum drug to multi-ligand and multifunctional platinum prodrugs over half a century. With the rapid development of metal drugs and the anticancer immune response, challenges and opportunities in platinum drug research have been shifted from traditional platinum-based drugs to platinum-based hybrids and the direction of development is tending toward photodynamic therapy, nano-delivery therapy, drug combination, targeted therapy, diagnostic therapy, immune-combination therapy and tumor stem cell therapy. In this review, we first exhaustively overviewed the role of platinum-based antitumor prodrugs and the anticancer immune response in medicinal inorganic chemistry based on the special nanomaterials, the modification of specific ligands, and the multiple functions obtained that are beneficial for tumor therapy in the last five years. We also categorized them according to drug potency and function. There hasn't been a comprehensive evaluation of precursor platinum drugs in prior articles. And a multifarious approach to distinguish and detail the variety of alterations of platinum-based precursors in various valence states also hasn't been summarized. In addition, this review points out the main problems at the interface of chemistry, biology, and medicine from their action mechanisms for current platinum drug development, and provides up-to-date potential strategies from drug design perspectives to circumvent those drawbacks. And a promising idea is also enlightened for researchers in the development and discovery of platinum prodrugs.

Anticancer immune response Metal drugs Photodynamic and photosensitization therapy Platinum-based antitumor drugs Tumor microenvironment regulation

SCI

英语

其他

Research and Development[2019B020202001];China Postdoctoral Science Foundation[2021M701089];Key Scientific Research Project of Colleges and Universities in Henan Province[222102310402];Natural Science Foundation of Henan Province[222300420409];Key Scientific Research Project of Colleges and Universities in Henan Province[22A350002];

Pharmacology & Pharmacy

Chemistry, Medicinal

WOS:000862665400005

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER

CHEMISTRY

2-s2.0-85138541833

Scopus

1.School of Pharmacy,Institute for Innovative Drug Design and Evaluation,Academy for Advanced Interdisciplinary Studies,Henan Province Engineering Research Center of High Value Utilization to Natural Medical Resource in Yellow River Basin,Henan University,Kaifeng,N. Jinming Ave,475004,China
2.The Key Laboratory of Natural Medicine and Immuno-Engineering,Henan University,Kaifeng,475004,China
3.Henan University Joint National Laboratory for Antibody Drug Engineering,School of Basic Medicine Science,Henan University,Kaifeng,China
4.School of Medicine,The Southern University of Science and Technology,Shenzhen,China

Su，Shihao,Chen，Yutong,Zhang，Pengfei,et al. The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2022,243.

Su，Shihao.,Chen，Yutong.,Zhang，Pengfei.,Ma，Ruijuan.,Zhang，Wei.,...&Ma，Jing.(2022).The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,243.

Su，Shihao,et al."The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 243(2022).